Strides Shasun gets USFDA nod for lipid lowering drug

By: | Published: September 20, 2017 3:19 PM

Drug firm Strides Shasun today said it has received approval from the United States health regulator for generic Omega-3-acid ethyl esters softgel capsules used for reducing lipid in the blood.

Strides Shasun, USFDA nod, lipid lowering drug, US Food and Drug Administration, health news, industry newsThe company’s has received approval from the US Food and Drug Administration (USFDA) for its capsules which are generic version of Lovaza capsules. (Representational Image: Reuters)

Drug firm Strides Shasun today said it has received approval from the United States health regulator for generic Omega-3-acid ethyl esters softgel capsules used for reducing lipid in the blood. The company’s has received approval from the US Food and Drug Administration (USFDA) for its capsules which are generic version of Lovaza capsules, Strides Shasun said in a filing to BSE.Strides Shasun has partnered with Par Pharmaceutical to market the product in the United States, it added.

Commenting on the development, Strides Shasun MD Shashank Sinha said: “We are delighted with this important product approval, which came through after a long approval cycle of almost 60 months, due to significant regulatory changes.” The product to be manufactured in the company’s Bengaluru facility and will be launched immediately, Strides Shasun said.

As per IMS, the US market for the generic Lovaza is approximately USD 300 million per annum, it added. “The company’s Omega-3-acid ethyl easters capsules are indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia”. Shares of Strides Shasun were today trading at Rs 1,026.50 per scrip in the afternoon trade on BSE, up 1.82 per cent from its previous close.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Switch to Hindi Edition